Jazz Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Jazz Pharmaceuticals (JAZZ).

Price Target Range — 10 Quarters

Analyst Consensus — 20 Analysts

18Buy

2Hold

Consensus RatingBuy# Analysts20Avg. Consensus PT$265Upside to Avg. PT+27.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	Morgan Stanley	Jeffrey Hung	PT Cut	Overweight	$322→$314
Oct 8, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$299→$296
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$281→$286
Sep 30, 2026	Citigroup	Geoff Meacham	Initiate	Buy	$325
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$337
Sep 11, 2026	UBS	Ashwani Verma	PT Raise	Buy	$315→$337
Sep 10, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$270→$271
Aug 26, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$287→$300
Aug 26, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$283→$322
Aug 26, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$264→$281
Aug 26, 2026	Needham	Ami Fadia	PT Raise	Buy	$292→$310
Aug 11, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$280→$283
Aug 4, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$265→$276
Aug 4, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$254→$264
Aug 4, 2026	TD Cowen	Joseph Thome	PT Raise	Buy	$275→$300
Aug 4, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$301→$310
Aug 4, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$285→$300
Aug 4, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$245→$280
Aug 4, 2026	Needham	Ami Fadia	PT Raise	Buy	$282→$292
Aug 4, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$260→$270

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target from $322 to $314.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $296

RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and lowers the price target from $299 to $296.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $281 to $286.

Benzinga Newsdesk

PRO
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and announces $337 price target.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

UBS analyst Ashwani Verma maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $315 to $337.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $270 to $271.

Benzinga Newsdesk

Jazz Pharmaceuticals PLC

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Jazz Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314

PRO
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $296

PRO
Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286

PRO
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

PRO
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

People Also Watch

People Also Watch

Jazz Pharmaceuticals PLC

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Jazz Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314

PRORBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $296

PROTruist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286

PROGoldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

PROUBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

PROBarclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314

PRO
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $296

PRO
Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286

PRO
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

PRO
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271